Author

Perla Pucci

University of CambridgeORCID 0000-0003-1264-3487Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

Benedetto GrimaldiiD· 1 shared Bengt HallbergiD· 1 shared Charlotte Barrett· 1 shared Cheryl A. HawkesiD· 1 shared Christopher Steel· 1 shared Elena JachettiiD· 1 shared Emily R. JamesiD· 1 shared Francesco CreaiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Benedetto GrimaldiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyEpigenomicsPeer-reviewedJan 29, 2025

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive variant prostate cancer

Maryam Latarani, Perla Pucci, Mark Eccleston…·Francesco Crea

This study shows that EZH2 inhibition enhances platinum chemotherapy effectiveness in aggressive variant prostate cancer by reducing H3K27me3 and modulating DNA repair and apoptosis pathways.

6 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 5, 2024

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg…·Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

1 citation

humangenetic perturbation / CRISPR

𝕏 PostBluesky